Baker Bros. Advisors LP Intellia Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$46.59 - $83.68 $5.19 Million - $9.31 Million	-111,296 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$18.83 - $63.53 $206,037 - $695,145	-10,942 Reduced 8.95%	111,296 $6.06 Million
Q3 2020 Nov 16, 2020	SELL	$17.47 - $24.93 $110,061 - $157,059	-6,300 Reduced 4.9%	122,238 $2.43 Million
Q4 2018 Feb 13, 2019	SELL	$11.39 - $27.13 $728,960 - $1.74 Million	-64,000 Reduced 33.24%	128,538 $1.76 Million
Q3 2018 Nov 14, 2018	SELL	$25.78 - $32.6 $9.14 Million - $11.6 Million	-354,384 Reduced 64.8%	192,538 $5.51 Million

Q2 2018 Aug 14, 2018	SELL	$20.02 - $30.79 $5.74 Million - $8.83 Million	-286,873 Reduced 34.41%	546,922 $15 Million
Q1 2018 May 15, 2018	SELL	$19.43 - $34.95 $6.06 Million - $10.9 Million	-311,658 Reduced 27.21%	833,795 $17.6 Million
Q4 2017 Feb 14, 2018	BUY	$17.39 - $31.12 $1.45 Million - $2.59 Million	83,333 Added 7.85%	1,145,453 $22 Million
Q3 2017 Nov 14, 2017	BUY	$15.16 - $25.75 $16.1 Million - $27.3 Million	1,062,120	1,062,120 $26.4 Million

313

89.3M

686K

599K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.7B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.